5 results match your criteria Journal of Diabetes Mellitus [Journal]

  • Page 1 of 1

Prevention of type 2 diabetes in urban American Indian/Alaskan Native communities: The Life in BALANCE pilot study.

J Diabetes Mellitus 2013 Nov;3(4):184-191

Department of Anthropology, University of Nevada Las Vegas, Las Vegas, USA.

Objective: The Life in BALANCE (LIB) study is a pilot translational study modeling the Diabetes Prevention Program (DPP) intensive lifestyle coaching intervention among an underserved, high-risk population: American Indians/Alaska Natives (AI/ANs) living in a large urban setting (Las Vegas, Nevada).

Research Design And Methods: A total of 22 overweight/obese AI/ANs (age, 39.6 ± 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/jdm.2013.34028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952556PMC
November 2013
30 Reads

12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.

J Diabetes Mellitus 2013 Aug;3(3)

Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, USA.

Background: Increased mitogen-activated protein kinase (MAPK) phosphorylation has been detected in peripheral nerve of human subjects and animal models with diabetes as well as high-glucose exposed human Schwann cells, and have been implicated in diabetic peripheral neuropathy. In our recent studies, leukocytetype 12/15-lipoxygenase inhibition or gene deficiency alleviated large and small nerve fiber dysfunction, but not intraepidermal nerve fiber loss in streptozotocin-diabetic mice.

Methods: To address a mechanism we evaluated the potential for pharmacological 12/15-lipoxygenase inhibition to counteract excessive MAPK phosphorylation in mouse and cell culture models of diabetic neuropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/jdm.2013.33015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808974PMC
August 2013
24 Reads

Differentially expressed genes in adipocytokine signaling pathway of adipose tissue in pregnancy.

J Diabetes Mellitus 2013 May;3(2):86-95

Department of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, USA.

Objective: To profile the differential gene expression of the KEGG Adipocytokine Signaling pathway in omental compared to subcutaneous tissue in normal pregnancy.

Study Design: Subjects included 14 nonobese, normal glucose tolerant, healthy pregnant women. Matched omental and subcutaneous tissue were obtained at elective cesarean delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/jdm.2013.32013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447103PMC
May 2013
17 Reads

Comparison of the fatty acid composition of the serum phospholipids of controls, prediabetics and adults with type 2 diabetes.

J Diabetes Mellitus 2012 Nov;2(4):393-401

Department of Biochemistry and Molecular Biology, University of New Mexico, Albuquerque, USA.

Objective: Although abnormalities in the fatty acid composition of serum and red cell membrane phospholipids of patients with type 2 diabetes are well-documented, lacking are studies of this issue in prediabetic individuals.

Materials/methods: For this cross-sectional study, we recruited 180 subjects (30-80 years), 56 of whom were normal with regard to glucose control (HbA1c, <5.7%), 61 who had prediabetes (HbA1c, 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/jdm.2012.24061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235577PMC
November 2012
30 Reads

Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline.

J Diabetes Mellitus 2012 May;2(2):251-257

Department of Medicine and the Strelitz Diabetes Center, Eastern Virginia Medicial School, Norfolk, USA.

Type 1 diabetes mellitus results from the autoimmune and inflammatory destruction of insulin-producing islet β cells, rendering individuals devoid of insulin production. Recent studies suggest that combination therapies consisting of anti-inflammatory agents and islet growth-promoting factors have the potential to cause sustained recovery of β cell mass, leading to amelioration or reversal of type 1 diabetes in mouse models. In this study, we hypothesized that the combination of the anti-inflammatory agent lisofylline (LSF) with an active peptide fragment of islet neogenesis associated protein (INGAP peptide) would lead to remission of type 1 diabetes in the non-obese diabetic (NOD) mouse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/jdm.2012.22040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603394PMC
May 2012
9 Reads
  • Page 1 of 1